CareDx, Inc. (CDNA) Form 8-K — Oct 29, 2026
$CDNAForm 8-KItems 2.02, 7.01, 9.01Filed Oct 29, 2026, 4:02 PM ET0001217234-26-000059Original filing
CareDx reported Q3 2026 revenue of $139 million, up 39% year-over-year, with Testing Services revenue of $119 million up 65% on volume growth of 51%, including contributions from the NavDx (Naveris) acquisition closed July 1, 2026 for $160 million cash plus up to $100 million contingent. GAAP net income jumped to $19 million ($0.35 diluted) from $2 million a year ago, and adjusted EBITDA doubled to $30 million, implying a 22% margin.
Key figures
- Eps
- GAAP diluted $0.35; non-GAAP diluted $0.70
- Revenue
- 139362000
- Guidance
- FY2026 revenue $520-530M (raised from $490-500M); FY2026 adjusted EBITDA $90-100M (raised from $66-78M)
- Net Income
- 19292000
- Revenue Yoy
- 39%
- Total Assets
- 641457000
- Cash Position
- 250480000
- Naveris deal
- $160M cash plus up to $100M contingent consideration, closed July 1, 2026
- Free cash flow
- $11.1M
- Testing volume
- ~75,900 tests, +51% YoY
- Adjusted ebitda
- $30.5M vs $15.3M year-ago
- Operating cash flow
- $12.7M
- Testing services revenue
- $119.2M, +65% YoY
- Patient digital solutions revenue
- $20.2M, +31% YoY
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.